EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudie

Diagnostic Accuracy of 68 Ga-FAPI Versus 18 F-FDG PET in Patients with Various Malignancies

Nader Hirmas, Rainer Hamacher, Miriam Sraieb, Lukas Kessler, Kim M Pabst, Francesco Barbato, Helena Lanzafame, Stefan Kasper, Michael Nader, Claudia Kesch, Bastian von Tresckow, Hubertus Hautzel und 12 weitere

Journal of Nuclear Medicine · 2024-03 · 65 (3) · 372-378

DOI: 10.2967/jnumed.123.266652 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.02.2024. Verfasst von Nader Hirmas und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany; naderhirmas@gmail.c…. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Neoplasms, Positron-Emission Tomography. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To assess the diagnostic accuracy of 68Ga-labeled fibroblast activation protein inhibitor (FAPI) and 18F-labeled FDG PET for the detection of various tumors, we performed a head-to-head comparison of both imaging modalities across a range of tumor entities as part of our ongoing 68Ga-FAPI PET observational trial.

Methods

The study included 115 patients with 8 tumor entities who received imaging with 68Ga-FAPI for tumor staging or restaging between October 2018 and March 2022. Of those, 103 patients received concomitant imaging with 68Ga-FAPI and 18F-FDG PET and had adequate lesion validation for accuracy analysis. Each scan was evaluated for the detection of primary tumor, lymph nodes, and visceral and bone metastases. True or false positivity and negativity to detected lesions was assigned on the basis of histopathology from biopsies or surgical excision, as well as imaging validation.

Results

68Ga-FAPI PET revealed higher accuracy than 18F-FDG PET in the detection of colorectal cancer (n = 14; per-patient, 85.7% vs. 78.6%; per-region, 95.6% vs. 91.1%) and prostate cancer (n = 22; per-patient, 100% vs. 90.9%; per-region, 96.4% vs. 92.7%). 68Ga-FAPI PET and 18F-FDG PET had comparable per-patient accuracy in detecting breast cancer (n = 16, 100% for both) and head and neck cancers (n = 10, 90% for both modalities). 68Ga-FAPI PET had lower per-patient accuracy than 18F-FDG PET in cancers of the bladder (n = 12, 75% vs. 100%) and kidney (n = 10, 80% vs. 90%), as well as lymphoma (n = 9, 88.9% vs. 100%) and myeloma (n = 10, 80% vs. 90%).

Conclusion

68Ga-FAPI PET demonstrated higher diagnostic accuracy than 18F-FDG PET in the diagnosis of colorectal cancer and prostate cancer, as well as comparable diagnostic performance for cancers of the breast and head and neck. Accuracy and impact on management will be further assessed in an ongoing prospective interventional trial (NCT05160051).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18NeoplasmsPositron-Emission TomographyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedQuinolines

Stichwörter der Autor:innen

FAPIFDGPETaccuracyoncologytheranostic

Substanzen

68Ga-FAPIFluorodeoxyglucose F18Quinolines

Autor:innen und Institutionen

  • Department of Nuclear Medicine, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany; naderhirmas@gmail.com.
  • Department of Medical Oncology, West German Cancer Center, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department of Nuclear Medicine, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department of Urology, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department of Thoracic Surgery and Thoracic Endoscopy, German Cancer Consortium-University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Zitieren

APA

Hirmas, N., Hamacher, R., Sraieb, M., Kessler, L., Pabst, K. M., Barbato, F., Lanzafame, H., Kasper, S., Nader, M., Kesch, C., von Tresckow, B., Hautzel, H., Aigner, C., Glas, M., Stuschke, M., Kümmel, S., Harter, P., Lugnier, C., Uhl, W., …, & Fendler, W. P. (2024). Diagnostic Accuracy of 68 Ga-FAPI Versus 18 F-FDG PET in Patients with Various Malignancies. Journal of Nuclear Medicine, 65(3), 372-378. https://doi.org/10.2967/jnumed.123.266652

Vancouver

Hirmas N, Hamacher R, Sraieb M, Kessler L, Pabst KM, Barbato F, et al. Diagnostic Accuracy of 68 Ga-FAPI Versus 18 F-FDG PET in Patients with Various Malignancies. Journal of Nuclear Medicine. 2024;65(3):372-378. doi:10.2967/jnumed.123.266652

BibTeX
@article{Hirmas2024,
  author = {Hirmas, Nader and Hamacher, Rainer and Sraieb, Miriam and Kessler, Lukas and Pabst, Kim M and Barbato, Francesco and Lanzafame, Helena and Kasper, Stefan and Nader, Michael and Kesch, Claudia and von Tresckow, Bastian and Hautzel, Hubertus and Aigner, Clemens and Glas, Martin and Stuschke, Martin and Kümmel, Sherko and Harter, Philipp and Lugnier, Celine and Uhl, Waldemar and Hadaschik, Boris and Grünwald, Viktor and Siveke, Jens T and Herrmann, Ken and Fendler, Wolfgang P},
  title = {Diagnostic Accuracy of 68 Ga-FAPI Versus 18 F-FDG PET in Patients with Various Malignancies},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {3},
  pages = {372--378},
  doi = {10.2967/jnumed.123.266652}
}
Kostenlos starten →